About: Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $7.51 (-1.57%)
XLO NASDAQ Xilio Development Inc
Xilio Development Inc share price
Atividade de preço de XLO
Último preço
$ 7,510
Variação (24h)
-0,12 USD (1,57%)
Volume
3.22K
Volume (média 4 sem.)
-
Abertura
$ 7,60
Variação do dia
$ 7,51 - $ 7,70
Fechamento anterior
$ 7,63
Último negócio
19 Nov, 9:00 pm GMT+0
Atrasado
19 Nov, 9:00 pm GMT+0
XLO price performance
Atrasado
19 Nov, 9:00 pm GMT+0
XLO details
quote.marketSignals